Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 75

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 75
---
|:------------------------------------------------------------------------------------------------------------|:----|:--------------|------------:|:--|:----|:-----------|-----------:|:--|:----|:-----------|------------:|:--|
| Preferred shares, CHF 0.80 par value, 206,452 registered shares issued and outstanding at December 31, 2024 |     | $             |   2,740,958 |   |     | $          | (2,574,605 | ) |     | $          |     166,353 |   |
| Common shares, CHF 0.80 par value, 3,159,535 registered shares issued and outstanding at December 31, 2024  |     |               |     166,353 |   |     |            |  2,574,605 |   |     |            |   2,740,958 |   |
| Additional paid-in capital                                                                                  |     |               |  72,820,671 |   |     |            |          — |   |     |            |  72,820,671 |   |
| Accumulated deficit                                                                                         |     |               | (74,430,474 | ) |     |            |          — |   |     |            | (74,430,474 | ) |
| Accumulated other comprehensive loss                                                                        |     |               |     108,853 |   |     |            |          — |   |     |            |     108,853 |   |
| Total shareholders’ equity (deficit)                                                                        |     | $             |   1,406,361 |   |     | $          |          — |   |     | $          |   1,406,361 |   |

As of December 31, 2024, preferred shares includes preferred participation certificates.

Annex A-20 NLS PHARMACEUTICS LTD.
NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Note 9 Subsequent Events: Management has evaluated subsequent events that have occurred through the date these unaudited interim condensed financial statements were issued. Warrant Exchange Agreement On August 5, 2025, the Company entered into a warrant exchange agreement (the “Exchange Agreement”) with Alpha. Pursuant to the terms of the Exchange Agreement, the Company and Alpha agreed to exchange a certain common share purchase warrant dated October 10, 2024 to purchase 207,913of